MWNA
ADMA icon

Marshall Wace North America’s ADMA Biologics ADMA Stock Holding History

Marshall Wace North America’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-84,560
Closed -$244K – 1126
2020
Q1 		$244K Buy
+84,560
New +$292K ﹤0.01% 872
2019
Q3 		– Sell
-291,538
Closed -$1.13M – 1287
2019
Q2 		$1.13M Buy
+291,538
New +$1.29M 0.01% 715

Other funds holding ADMA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Marshall Wace North America's ADMA Position: Q2 2020 in Review

Marshall Wace North America sold out of ADMA Biologics (ADMA) in Q2 2020, closing a stake of 84,560 shares — an estimated $244K sold.

Marshall Wace North America first reported a position in ADMA in Q2 2019 and held it in 2 quarters. The position peaked at $1.13M in Q2 2019. 95 funds tracked by Wall St. Rank hold ADMA as of Q2 2020.

  • Marshall Wace North America reported no remaining ADMA Biologics position as of Q2 2020 after selling out during the quarter.
  • Marshall Wace North America sold 84,560 ADMA Biologics shares in Q2 2020, an estimated $244K.
  • Marshall Wace North America first reported a position in ADMA Biologics in Q2 2019 and held it in 2 quarters.
  • Marshall Wace North America's ADMA Biologics position peaked at $1.13M in Q2 2019.
  • 95 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2020.

Based on Marshall Wace North America's 13F filing for Q2 2020, filed 13 Aug 2020.